Tag:
Gilead Sciences
Latest Headlines
Latest Headlines
The biggest R&D spenders in biotech
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
FDA panel OKs Gilead's key HIV drug Quad
The four-in-one pill for HIV won support from an FDA advisory committee Friday, bolstering the Foster City, CA-based company's efforts to gain approval of the drug and maintain its top position in the market for HIV and AIDS drugs.
FDA advisory panel backs Truvada for HIV prevention
It is two down and one to go for Truvada, the Gilead Sciences ($GLD) HIV medication. An FDA advisory panel, following the lead of the agency staff, recommended 19-3 that the drug be prescribed to people at high risk as a preventive against HIV infection.
FDA details kidney damage in Gilead's Quad studies
The kidney damage could warrant monitoring of patients taking the drug, the FDA staff briefing said, according to Bloomberg .
Advisory panels take up Gilead's Truvada, then Quad
It will be up to an advisory panel to say whether Truvada's potential is undercut by the chance patients won't take it or that drug resistance is too likely.
Truvada up for FDA debate as HIV preventive
Should an HIV treatment become a prophylactic? That's the question an FDA panel will address later this week.
Lack of Gilead and BMS teamwork on hep C draws ire
Gilead Sciences' reluctance to strike a collaboration deal with Bristol-Myers Squibb on a combo hepatitis C treatment has ruffled some feathers in the clinical community.
FDA hits brakes on Novartis' hep C program after death
U.S. regulators have put a hold on Novartis' clinical trial for experimental hepatitis C drug alisporivir after cases of pancreatitis were reported in the trial and one patient in the study died.
Adimab adds Gilead pact to its growing roster of antibody deals
Gilead Sciences--in the news today with some stellar hep C data--has turned to Adimab to work on antibodies for two undisclosed targets.
Gilead wows analysts as 7977 combos quell hep C in most patients
The treatment that may well have the inside track in the hectic race to create the first all-oral combo treatment for hepatitis C.
